Literature DB >> 26250458

The critical role of HMGA2 in regulation of EMT in epithelial ovarian carcinomas.

Junyuan Yan1, Yanling Zhang2, Wenshuang Shi2, Cuili Ren2, Yan Liu1, Yunyan Pan3.   

Abstract

The high mobility group A2 (HMGA2), an oncofetal protein, was shown to play a role in tumor development and progression. However, the molecular and clinical role of HMGA2 in epithelial ovarian carcinomas (EOCs) is still unknown. In the present study, EOC cell line SKOV3 was subjected to in vitro assays. Here, our findings showed that HMGA2 was highly expressed in EOC cell line SKOV3. HMGA2 knockdown promoted cell apoptosis and the cleavage of caspase 3, and decreased the B cell lymphoma 2 (Bcl-2)/Bax ratio in SKOV3. Functionally, HMGA2 knockdown resulted in reduction of SKOV3 cell migration and invasion. Mechanically, HMGA2 knockdown affected the occurrence of EMT by increasing E-cadherin gene and protein expression and decreasing the gene and protein expression of N-cadherin, slug, and vimentin. At the same time, HMGA2 also repressed the expression of matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MMP9), which was consistent with the decreased invasion capacity. In conclusion, HMGA2 is associated with migration and invasiveness and regulates the progression of EMT in the development of EOC, and HMGA2 gene and protein may be a novel therapeutic target against EOC in the clinical practice.

Entities:  

Keywords:  EMT; Epithelial ovarian carcinomas; HMGA2

Mesh:

Substances:

Year:  2015        PMID: 26250458     DOI: 10.1007/s13277-015-3852-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  20 in total

1.  BAG3 protein delocalisation in prostate carcinoma.

Authors:  Stefania Staibano; Massimo Mascolo; Maria Di Benedetto; Maria Luisa Vecchione; Gennaro Ilardi; Giuseppe Di Lorenzo; Riccardo Autorino; Vincenzo Salerno; Antonella Morena; Alba Rocco; Maria Caterina Turco; Emilio Morelli
Journal:  Tumour Biol       Date:  2010-06-10

Review 2.  Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators.

Authors:  Marc-André C Déry; Maude D Michaud; Darren E Richard
Journal:  Int J Biochem Cell Biol       Date:  2005-03       Impact factor: 5.085

3.  BAG3 controls angiogenesis through regulation of ERK phosphorylation.

Authors:  A Falco; M Festa; A Basile; A Rosati; M Pascale; F Florenzano; S L Nori; V Nicolin; M Di Benedetto; M L Vecchione; C Arra; A Barbieri; V De Laurenzi; M C Turco
Journal:  Oncogene       Date:  2012-02-06       Impact factor: 9.867

Review 4.  Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

Authors:  Philipp Harter; Felix Hilpert; Sven Mahner; Florian Heitz; Jacobus Pfisterer; Andreas du Bois
Journal:  Expert Rev Anticancer Ther       Date:  2010-01       Impact factor: 4.512

5.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

6.  Characterization of BAG3 cleavage during apoptosis of pancreatic cancer cells.

Authors:  Hua-Qin Wang; Xin Meng; Yan-Yan Gao; Bao-Qin Liu; Xiao-Fang Niu; Hai-Yan Zhang; Zhen-Xian Du
Journal:  J Cell Physiol       Date:  2010-07       Impact factor: 6.384

7.  The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  Gennaro Chiappetta; Massimo Ammirante; Anna Basile; Alessandra Rosati; Michela Festa; Mario Monaco; Emilia Vuttariello; Rosa Pasquinelli; Claudio Arra; Monica Zerilli; Matilde Todaro; Giorgio Stassi; Luciano Pezzullo; Antonio Gentilella; Alessandra Tosco; Maria Pascale; Liberato Marzullo; Maria Antonietta Belisario; Maria Caterina Turco; Arturo Leone
Journal:  J Clin Endocrinol Metab       Date:  2006-12-12       Impact factor: 5.958

Review 8.  Biology of hepatocellular carcinoma.

Authors:  Roberta W C Pang; Jae Won Joh; Philip J Johnson; Morito Monden; Timothy M Pawlik; Ronnie T P Poon
Journal:  Ann Surg Oncol       Date:  2008-01-31       Impact factor: 5.344

9.  Enhanced autophagy blocks angiogenesis via degradation of gastrin-releasing peptide in neuroblastoma cells.

Authors:  Kwang Woon Kim; Pritha Paul; Jingbo Qiao; Sora Lee; Dai H Chung
Journal:  Autophagy       Date:  2013-08-29       Impact factor: 16.016

10.  PKCδ-mediated phosphorylation of BAG3 at Ser187 site induces epithelial-mesenchymal transition and enhances invasiveness in thyroid cancer FRO cells.

Authors:  N Li; Z-X Du; Z-H Zong; B-Q Liu; C Li; Q Zhang; H-Q Wang
Journal:  Oncogene       Date:  2012-10-29       Impact factor: 9.867

View more
  6 in total

1.  Silencing of HMGA2 suppresses cellular proliferation, migration, invasion, and epithelial-mesenchymal transition in bladder cancer.

Authors:  Zhan Shi; Xiang Li; Ding Wu; Run Tang; Renfu Chen; Song Xue; Xiaoqing Sun
Journal:  Tumour Biol       Date:  2015-12-18

2.  The involvement of anterior gradient 2 in the stromal cell-derived factor 1-induced epithelial-mesenchymal transition of glioblastoma.

Authors:  Chunhua Xu; Yue Liu; Limin Xiao; Changgui Guo; Shengze Deng; Suyue Zheng; Erming Zeng
Journal:  Tumour Biol       Date:  2015-11-25

3.  The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer.

Authors:  Ikbale El Ayachi; Iram Fatima; Peter Wend; Jackelyn A Alva-Ornelas; Stephanie Runke; William L Kuenzinger; Julio Silva; Wendy Silva; Joseph K Gray; Stephan Lehr; Hilaire C Barch; Raisa I Krutilina; Andrew C White; Robert Cardiff; Lisa D Yee; Lily Yang; Ruth M O'Regan; William E Lowry; Tiffany N Seagroves; Victoria Seewaldt; Susan A Krum; Gustavo A Miranda-Carboni
Journal:  Cancer Res       Date:  2018-12-18       Impact factor: 13.312

4.  Cell-based high-throughput compound screening reveals functional interaction between oncofetal HMGA2 and topoisomerase I.

Authors:  Sabrina Peter; Haojie Yu; Roland Ivanyi-Nagy; Peter Dröge
Journal:  Nucleic Acids Res       Date:  2016-09-01       Impact factor: 16.971

5.  Oncogenic role of HMGA2 in fusion-negative rhabdomyosarcoma cells.

Authors:  Kazutaka Ouchi; Mitsuru Miyachi; Shigeki Yagyu; Ken Kikuchi; Yasumichi Kuwahara; Kunihiko Tsuchiya; Tomoko Iehara; Hajime Hosoi
Journal:  Cancer Cell Int       Date:  2020-05-24       Impact factor: 5.722

6.  microRNA-98 inhibits the proliferation, invasion, migration and promotes apoptosis of breast cancer cells by binding to HMGA2.

Authors:  Mi-Jia Wang; Hao Zhang; Jun Li; Hai-Dong Zhao
Journal:  Biosci Rep       Date:  2018-09-19       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.